| Predicate |
Object |
| contentType |
Comment|Letter |
| issn |
0041-5782 |
| issueIdentifier |
20 |
| pageRange |
2200; author reply 2200- |
| publicationName |
Ugeskrift for laeger |
| startingPage |
2200; author reply 2200 |
| bibliographicCitation |
Lindholm J. [The Medical Products Agency and testosterone treatment. Act II]. Ugeskr Laeger. 2005 May 16;167(20):2200; author reply 2200. PMID: 15987085. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fce9e122dbee29ae7f2b13d1ca7c4a9e |
| date |
2005-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/15987085 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/7874
https://portal.issn.org/resource/ISSN/0041-5782 |
| language |
Danish |
| source |
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
[The Medical Products Agency and testosterone treatment. Act II] |
| discusses |
http://id.nlm.nih.gov/mesh/M0056567
http://id.nlm.nih.gov/mesh/M0025275
http://id.nlm.nih.gov/mesh/M0021196 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D013739Q000627
http://id.nlm.nih.gov/mesh/D013739Q000031 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D004346
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D016568
http://id.nlm.nih.gov/mesh/D008297 |